Now available: Apaly Rx. Transparent, cost-plus prescription pricing, integrated with APC+. Learn more →

NewsEmployers/Partners

Apaly Health Inc. Unveils Apaly Rx to Lower GLP1 Costs for Self Funded Employers

AH
Apaly Health
Apaly Health Inc. Unveils Apaly Rx to Lower GLP1 Costs for Self Funded Employers

Published October 10, 2025 · Updated May 15, 2026

10/9/2025

Apaly Rx is a first-of-its-kind solution that automatically routes high-cost medication prescriptions (starting with GLP-1s for obesity and diabetes) to the lowest net-cost, plan-approved fulfillment channel.

For Immediate Release

Apaly Health Inc. Unveils Apaly Rx: Dynamic Rx Routing to Lowest Net-Cost GLP-1 Fulfillment for Self-Funded Employers and Commercial Health Plans.

TAMPA, Fla., September 30, 2025 - Apaly today announced Apaly Rx, a first-of-its-kind solution that automatically routes high-cost medication prescriptions (starting with GLP-1s for obesity and diabetes) to the lowest net-cost, plan-eligible fulfillment channel. Built to help self-funded employers and commercial health plans manage accelerating pharmacy spend without sacrificing access, Apaly Rx operates independently or alongside existing GLP-1 and weight-management programs to reduce per-unit costs and sustain coverage.

Employer pharmacy costs tied to GLP-1 use have surged, with PMPM spend jumping markedly and GLP-1s now accounting for a meaningful share of total claims for many plans. In response, sponsors are tightening criteria, shifting cost sharing, and even considering carve-outs. At the same time, the clinical benefits of GLP-1s are compelling: beyond significant weight loss for many patients, semaglutide has demonstrated cardiovascular risk reduction, benefits that make outright exclusions a blunt instrument. Plans need tools that balance affordability and outcomes.

How Apaly Rx Works

Apaly Rx ingests plan rules, member eligibility, and responsibility, then dynamically routes each prescription across plan-approved, Apaly administered fulfillment channels, identifying the lowest net cost option. Apaly administers fulfillment, bills plan charges through claims, and automatically pays pharmacies, creating a seamless experience for members and administrators alike. Because net pricing can vary widely across channels and over time, Apaly Rx delivers continuous, point-of-order optimization that complements existing utilization management, step therapy, and coaching programs.

“Employers are facing real budget shock from GLP-1s. PMPM has risen sharply, and these therapies can represent a sizable slice of total plan claims,” said Jerry Beinhauer, MD, CEO and Founder of Apaly. “We speak with sponsors every day who are tightening criteria or even carving GLP-1s out because the spend feels unsustainable. That’s a lose-lose: members lose access and both plans and members lose long-term health benefits. Apaly Rx changes the equation by routing each fill to the lowest net-cost option allowed by the plan, containing spend without blanket exclusions.”

“Some health plans want a turnkey savings layer; others already run GLP-1 and weight-loss programs with coaching or prior-auth rules,” Beinhauer added. “Apaly Rx works either way, as a standalone optimization engine or in conjunction with those programs. Our goal is simple: lower the per-unit cost so employers can responsibly cover GLP-1s and deliver better cardiometabolic outcomes for their people.”

Coordinating With Apaly’s APC+

When Apaly Rx for GLP-1s is paired with Apaly’s Advanced Primary Care Plus (APC+), sponsors get a unified strategy: APC+ provides clinician-led intake, evidence-based cardiometabolic pathways, and ongoing coaching to ensure GLP-1 therapy for weight loss is medically appropriate, prioritizing lifestyle interventions first and de-escalation when goals are met. For members who meet criteria, Apaly Rx then routes each prescription to the lowest net-cost eligible channel. Together, they reduce avoidable GLP-1 utilization and lower per-unit drug costs, preserving access without sacrificing affordability.

Looking ahead, Apaly designed Apaly Rx as a reusable framework for any category with volatile net pricing: GLP-1s today, oncology and autoimmune biologics next. “What we’ve built isn’t a single-product tool,” said Dr. Beinhauer. “It’s a modular routing and payment engine we can extend to other high-cost therapies by plugging in the right clinical criteria and channels, so plans keep finding the lowest net-cost path as markets evolve.”

Availability

Apaly Rx is available now to self-funded employers, brokers, TPAs, and commercial health plans. To learn more or request a demo, visit www.apalyrx.com.

About Apaly

Apaly is a healthcare technology company based in Tampa, Florida, focused on addressing the root causes of increasing self-funded employer healthcare spend. Founded by Jerry Beinhauer, MD (CEO), Apaly builds solutions that align incentives for employers, providers, and members.

Media Contact kallan@apaly.com | (813) 938-6626 Learn more: www.apalyrx.com

Apaly Health Inc. Unveils Apaly Rx to Lower GLP1 Costs for Self Funded Employers
NewsEmployers/Partners

Apaly Health Inc. Unveils Apaly Rx to Lower GLP1 Costs for Self Funded Employers

AH
Apaly Health

Published October 10, 2025 · Updated May 15, 2026

10/9/2025

Apaly Rx is a first-of-its-kind solution that automatically routes high-cost medication prescriptions (starting with GLP-1s for obesity and diabetes) to the lowest net-cost, plan-approved fulfillment channel.

For Immediate Release

Apaly Health Inc. Unveils Apaly Rx: Dynamic Rx Routing to Lowest Net-Cost GLP-1 Fulfillment for Self-Funded Employers and Commercial Health Plans.

TAMPA, Fla., September 30, 2025 - Apaly today announced Apaly Rx, a first-of-its-kind solution that automatically routes high-cost medication prescriptions (starting with GLP-1s for obesity and diabetes) to the lowest net-cost, plan-eligible fulfillment channel. Built to help self-funded employers and commercial health plans manage accelerating pharmacy spend without sacrificing access, Apaly Rx operates independently or alongside existing GLP-1 and weight-management programs to reduce per-unit costs and sustain coverage.

Employer pharmacy costs tied to GLP-1 use have surged, with PMPM spend jumping markedly and GLP-1s now accounting for a meaningful share of total claims for many plans. In response, sponsors are tightening criteria, shifting cost sharing, and even considering carve-outs. At the same time, the clinical benefits of GLP-1s are compelling: beyond significant weight loss for many patients, semaglutide has demonstrated cardiovascular risk reduction, benefits that make outright exclusions a blunt instrument. Plans need tools that balance affordability and outcomes.

How Apaly Rx Works

Apaly Rx ingests plan rules, member eligibility, and responsibility, then dynamically routes each prescription across plan-approved, Apaly administered fulfillment channels, identifying the lowest net cost option. Apaly administers fulfillment, bills plan charges through claims, and automatically pays pharmacies, creating a seamless experience for members and administrators alike. Because net pricing can vary widely across channels and over time, Apaly Rx delivers continuous, point-of-order optimization that complements existing utilization management, step therapy, and coaching programs.

“Employers are facing real budget shock from GLP-1s. PMPM has risen sharply, and these therapies can represent a sizable slice of total plan claims,” said Jerry Beinhauer, MD, CEO and Founder of Apaly. “We speak with sponsors every day who are tightening criteria or even carving GLP-1s out because the spend feels unsustainable. That’s a lose-lose: members lose access and both plans and members lose long-term health benefits. Apaly Rx changes the equation by routing each fill to the lowest net-cost option allowed by the plan, containing spend without blanket exclusions.”

“Some health plans want a turnkey savings layer; others already run GLP-1 and weight-loss programs with coaching or prior-auth rules,” Beinhauer added. “Apaly Rx works either way, as a standalone optimization engine or in conjunction with those programs. Our goal is simple: lower the per-unit cost so employers can responsibly cover GLP-1s and deliver better cardiometabolic outcomes for their people.”

Coordinating With Apaly’s APC+

When Apaly Rx for GLP-1s is paired with Apaly’s Advanced Primary Care Plus (APC+), sponsors get a unified strategy: APC+ provides clinician-led intake, evidence-based cardiometabolic pathways, and ongoing coaching to ensure GLP-1 therapy for weight loss is medically appropriate, prioritizing lifestyle interventions first and de-escalation when goals are met. For members who meet criteria, Apaly Rx then routes each prescription to the lowest net-cost eligible channel. Together, they reduce avoidable GLP-1 utilization and lower per-unit drug costs, preserving access without sacrificing affordability.

Looking ahead, Apaly designed Apaly Rx as a reusable framework for any category with volatile net pricing: GLP-1s today, oncology and autoimmune biologics next. “What we’ve built isn’t a single-product tool,” said Dr. Beinhauer. “It’s a modular routing and payment engine we can extend to other high-cost therapies by plugging in the right clinical criteria and channels, so plans keep finding the lowest net-cost path as markets evolve.”

Availability

Apaly Rx is available now to self-funded employers, brokers, TPAs, and commercial health plans. To learn more or request a demo, visit www.apalyrx.com.

About Apaly

Apaly is a healthcare technology company based in Tampa, Florida, focused on addressing the root causes of increasing self-funded employer healthcare spend. Founded by Jerry Beinhauer, MD (CEO), Apaly builds solutions that align incentives for employers, providers, and members.

Media Contact kallan@apaly.com | (813) 938-6626 Learn more: www.apalyrx.com

Related Resources